Results 21 to 30 of about 1,312,052 (154)

Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain.
Seung Min Jung, Seung-Ki Kwok, Ji Hyeon Ju, Yong-Beom Park, Sung-Hwan Park   +4 more
doaj   +1 more source

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence

Gut and Liver, 2022
Background/Aims: Many patients with Crohn’s disease (CD) undergo intestinal resection during the disease course. Despite surgery, postoperative recurrence (POR) commonly occurs.
Jongwook Yu, Hye Kyung Hyun, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon   +8 more
doaj   +1 more source

Characteristics and management of ocular sarcoidosis

Immunological Medicine, 2022
Sarcoidosis is a chronic inflammatory disease of unknown etiology that affects many systemic organs, including the eye. The eye is the second most frequently affected organ in patients with sarcoidosis after lung disease. Approximately 30–50% of patients
Hiroshi Takase
doaj   +1 more source

Structure-Based Drug Design and Synthesis of Pyrrolidine-2,5-diones as Novel TNF‑α Inhibitors

, 2023
Tumor necrosis factor α (TNF-α) inhibitors are the treatment of choice for autoimmune diseases including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn’s disease.
Hua Li (46469), Hui Wang (30400), Lixia Chen (614030), Yang Liu (4829), Kuiru Sa (16046234), Yueying Yang (8058824), Yu Lin (370243)   +6 more
core   +3 more sources

The metabolic effects of TNF inhibitors in rheumatoid arthritis patients [PDF]

Romanian Journal of Rheumatology, 2019
Objective. Cardiovascular disease (CVD) is considered to be the main cause of morbidity and mortality in rheumatoid arthritis (RA) patients. Tumor necrosis factor alpha (TNF), an important pro-inflammatory cytokine, has a multivalent role in the ...
Alexandra Jitaru, Maria Magdalena Leon-Constantin, Cristina Pomirleanu, Codrina Ancuta, Florin Mitu   +4 more
doaj   +1 more source

Immunogenicity of TNF-Inhibitors

Frontiers in Immunology, 2020
Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either primary or
Sadaf Atiqi, Femke Hooijberg, Floris C. Loeff, Theo Rispens, Gerrit J. Wolbink, Gerrit J. Wolbink   +5 more
doaj   +1 more source

Are TNF inhibitors still the agent of choice for RA? [PDF]

, 2023
Since entering the clinic 25 years ago, biologic TNF inhibitors have transformed the outlook for people with rheumatoid arthritis and set the standard for all other targeted therapies. Despite changes to the therapeutic landscape, TNF inhibitors look set

core   +1 more source

Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.

PLoS ONE, 2021
In this study we aimed to identify the predictors of drug survival for biologic and targeted synthetic DMARDs (bDMARDs and tsDMARDs) among patients with rheumatoid arthritis (RA) in a real-world setting.
Ching-Tsai Lin, Wen-Nan Huang, Wen-Chan Tsai, Jun-Peng Chen, Wei-Ting Hung, Tsu-Yi Hsieh, Hsin-Hua Chen, Chia-Wei Hsieh, Kuo-Lung Lai, Kuo-Tung Tang, Chih-Wei Tseng, Der-Yuan Chen, Yi-Hsin Chen, Yi-Ming Chen   +13 more
doaj   +1 more source

Clinical Pharmacology Aspects in Patients Treated with TNF Inhibitors During SARS-Cov-2 Pandemic [PDF]

Advanced Pharmaceutical Bulletin, 2021
In this period of global pandemic caused by SARS-Cov-2, it is of paramount importance to recognize all risk factors that may increase the likelihood of infection.
Francesco Ferrara, Priscilla Santilli, Vilma D'Aiuto, Antonio Vitiello   +3 more
doaj   +1 more source

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study

Dermatology and Therapy, 2023
Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors.
Megumi Kishimoto, Mayumi Komine, Koji Kamiya, Junichi Sugai, Aya Kuwahara, Makiko Mieno, Mamitaro Ohtsuki   +6 more
doaj   +1 more source